[ORGANIZATION]
amlitelimab
Featured in 2 tracked stories · first seen
Situations
Sanofi halts Amlitelimab development
2 clusters · 11 sources · last updated
Latest: Sanofi Halts Development of Amlitelimab for Atopic Dermatitis
In late July 2026, Sanofi announced it would stop pursuing its experimental antibody Amlitelimab for atopic dermatitis. The company cited insufficient efficacy and safety data from the Phase 3 COAST‑1 trial, including is
Also covered in
-
Sanofi Raises 2026 Revenue Target After Strong Mid‑Year Results
[BUSINESS] · 2 sources ·